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To the Editor:
We would like to thank Niemczyk et al.
ing our manuscript [2] and taking the time to
comments. We would like, however, to cla
the criticisms they made:
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Carrion et al. [1] suggested that antiviral therapy in pa-
tientswithHCV cirrhosis before liver transplantationwas
quite successful in terms of virological response, and may
prevent a recurrence of HCV infection in the graft. How-
ever, it should be underlined that the authors used only
surrogate endpoints. The main hard endpoint, which is
death of the patient, was omitted in the discussion. On
the intention-to-treat basis, in the treated group the pre-
transplant mortality was fourfold higher compared to
the untreated group (4 vs. 1). The lack of statistical signif-
icance is secondary to the small number of patients in both
groups, but who can state it would still be observed if the
groups were more numerous? Additionally, it should be
mentioned that 4 other patients in the treated group were
excluded from the waiting list, which means that they
most probably also died, compared to none in the un-
treated group. Moreover, antiviral treatment prior to li-
ver transplantation in the HCV-infected patients was
previously reported to be connected to more frequent
and earlier recurrence in the transplant, and with in-
creased post-transplant mortality, compared to the un-
treated group [2]. Therefore, in our opinion, the risk of
pre-transplant anti-HCV therapy in cirrhotic patients is
not limited to bacterial infections and myelotoxicity, but
is muchmore complex. In summary, liver transplantation
is a life-saving procedure and mortality, as the hard end-
point, should never be omitted in such analyses. The ran-
domized clinical studies including large number of
patients and long-term post-transplant follow-up shouldCV-infect
ver transp
[1] for read-
make some
rify some ofbe performed to enable valuable conclusions concerning
eﬃcacy and safety of antiviral therapy preceding liver
transplantation in HCV cirrhotic patients.
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1. First, contrary to what was claimed we did not
omit the survival endpoint in the manuscript. In fact,
in the Results section of the paper [2] we clearly state
that 5 patients died before LT (4 from the treated group,
1 from the control group) and that 2 from the treated
